Skip to main content

TURP — Transurethral Resection of the Prostate

Transurethral Resection of the Prostate (TURP) is the surgical treatment for LUTS secondary to BPH that has long been called the "gold standard" (Mayer 2012, Rassweiler 2006).[7][13] It is the reference comparator for newer surgical and minimally invasive therapies.[1][2][3] The AUA 2026 guideline states that clinicians should offer bipolar or monopolar TURP as an option for LUTS/BPH .[21] For positioning against other BPH options, see BPH & Male LUTS — chooser.

Mechanism​

An electrosurgical loop is passed through a resectoscope and used to resect obstructing prostatic adenoma piecemeal. The loop cuts tissue and coagulates blood vessels at the same time. Resected chips fall into the bladder and are evacuated at the end of the procedure, providing tissue for histological analysis; incidental prostate cancer is detected in approximately 9.8% of TURP specimens.[4]

Monopolar TURP (M-TURP)​

  • Single active electrode (the loop); current passes through the patient's body to a return pad.
  • Requires nonconductive, electrolyte-free irrigation (glycine, sorbitol or mannitol); absorption can cause TUR syndrome with dilutional hyponatremia and fluid overload.[23] Solution osmolality varies: 5% mannitol irrigation is approximately isotonic.[36]
  • Resection time is limited to approximately 60–90 minutes to minimize fluid-absorption risk.[5][6]

TUR syndrome presents across a spectrum, from mild and nonspecific symptoms such as nausea or confusion to seizures, cardiorespiratory distress and coma when a large volume of irrigant is absorbed.[23] Severe neurologic or cardiorespiratory symptoms from dilutional hyponatremia (such as seizures, coma or cardiorespiratory distress) require urgent bolus hypertonic saline and serum-sodium monitoring. The target is an initial 4–6 mEq/L rise within 1–2 hours, with correction limited to 10 mEq/L in the first 24 hours.[24] Milder symptoms require assessment of sodium and volume status before treatment; the TUR-syndrome review favors hypertonic saline over diuretics when sodium correction is required.[23] Checking electrolytes in the recovery room helps identify a subclinical case.

Bipolar TURP (B-TURP)​

  • In bipolar TURP, current returns through a pole on the resectoscope tip or sheath, so it does not travel through the body to a skin pad.[22]
  • Uses normal saline (0.9% NaCl), avoiding classic dilutional hyponatremic TUR syndrome from electrolyte-free irrigant absorption.[22] The Cochrane review nevertheless retained trial-reported TUR-syndrome events as an outcome and estimated about 4 per 1,000 with bipolar versus 24 per 1,000 with monopolar TURP (RR 0.17).[5]
  • Allows longer resection times and may reduce thermal damage to surrounding tissues.[5]

Procedure​

TURP is performed under general or spinal or regional anesthesia. Operative time is typically 30–60 min depending on size.[2][7][6] The EAU 2026 Urological Infections guideline strongly recommends screening for and treating asymptomatic bacteriuria before mucosa-breaching procedures, and giving antibiotic prophylaxis for TURP.[27]

  1. 24–28 Fr resectoscope introduced through the urethra under direct vision.
  2. Bladder inspected for stones, diverticula, or tumors.
  3. Identify landmarks: bladder neck (proximal), verumontanum (distal limit of resection), external sphincter.
  4. Systematic resection, typically median lobe first (if present), then lateral lobes, working from bladder neck distally toward verumontanum.
  5. Create a midline trench to allow the lateral lobe to fall backward, then resect remaining adenoma while preserving the thin surgical capsule.
  6. Hemostasis: coagulate arterial bleeders (typically at 1, 5, 7, 11 o'clock).
  7. Tissue chips evacuated using Ellik evacuator.
  8. Three-way Foley placed for continuous bladder irrigation.

Operative parameters (pooled contemporary RCTs)[7]​

  • Mean resection time: 38.5 min
  • Mean resected tissue: 25.8 g
  • Mean catheterization: 2.5 d
  • Mean length of stay: 3.6 d (varies by country and practice)

Preoperative bleeding considerations​

In a 2026 meta-analysis of randomized TURP trials, preoperative finasteride or dutasteride reduced intraoperative blood loss versus placebo or no treatment in 11 trials (1,200 men; mean difference 82.6 mL less blood loss) and transfusions in 14 trials (1,181 men; OR 0.33, 95% CI 0.17–0.66).[37] EAU 2026 describes the clinical significance of preoperative 5-alpha-reductase inhibitors for bleeding as mixed.[22]

VTE prophylaxis​

TURP has a specific recommendation, unlike most BPH procedures: ASH 2019 conditionally suggests against routine pharmacologic VTE prophylaxis on very low-certainty evidence, though prior VTE, thrombophilia or malignancy may change that default.[28] See the VTE Prophylaxis page for that guidance and the broader urologic-surgery risk framework.

Patient selection​

Based on the AUA and EAU 2026 guidelines[21][22]:

  • EAU 2026 strongly recommends offering monopolar or bipolar TURP to men with moderate-to-severe LUTS and a 30–80 mL prostate (level 1a). The 80 mL upper limit is Panel consensus and depends on surgeon experience, resectoscope size and resection speed. Complication rates rise with gland size and with resection time, and EAU describes TURP as safest when completed in under 90 minutes.[22]
  • Bothersome moderate-to-severe LUTS (IPSS 8–35) inadequately relieved by conservative or medical treatment, or an absolute indication for surgery listed below.[22]
  • The AUA Panel’s expert opinion is that monopolar TURP is best used for prostates up to about 80 cc.[21] EAU 2026 recommends both monopolar and bipolar TURP for prostates of 30–80 mL.[22] The AUA 2026 Panel could not recommend a specific volume cutoff and gave as expert opinion that monopolar TURP is best used for glands ≤ 80 cc.[21] A prospective comparative study reported TURP in glands of 70–150 mL.[8] The Cochrane review compares bipolar with monopolar TURP.[5] The AUA 2026 guideline recommends offering simple prostatectomy as an option for prostates >80 cc and laser enucleation as an option without a size cutoff .[21]
  • Absolute indications. EAU 2026 lists recurrent or refractory urinary retention, overflow incontinence, recurrent UTI, bladder stones or diverticula, treatment-resistant macroscopic hematuria from BPH, and upper-tract dilatation from obstruction with or without renal insufficiency.[22]
  • Treats obstructive median lobes.
  • Provides tissue for histological analysis, which allows incidental prostate cancer detection.

Clinical efficacy​

The JAMA review describes TURP among treatments for refractory or complicated BPH that improve IPSS by about 10–15 points.[3] The table's 12- and 60-month IPSS/Qmax changes come from the TURP arm of WATER (65 recipients at baseline with 30–80 mL glands; 32 had five-year follow-up), reported in separate 1- and 5-year papers.[29][30] Baseline Qmax and PVR are from the Bavarian cohort.[4]

ParameterBaseline12 months60 months
IPSS~ 22–24−15.1−13.2
Qmax (mL/s)~ 10.4+10.6+6.3
PVR (mL), Bavarian cohort180.331.1 early postoperative; 12-month value not reported—
IPSS-QoL (0–6 scale; WATER TURP arm)4.8—1.6[32]

A meta-analysis of 20 RCTs confirmed 70% IPSS reduction and 69% QoL improvement with up to 5 yr follow-up.[1] The JAMA review treats TURP as the reference procedure for comparison with newer surgical options.[3]

A prospective comparative study of TURP in 56 men with prostates of 70–150 mL and 57 with smaller glands found larger improvements in IPSS and Qmax in the larger glands, longer operative time and similar complication rates.[8] At 1 yr PVR was lower in the smaller-gland group.

Monopolar vs Bipolar — the Cochrane comparison​

The 2019 Cochrane systematic review (59 RCTs, 8,924 participants) compared the two directly.[5]

ParameterM-TURPB-TURPSignificance
IPSS / Qmax / QoL / IIEFsimilarsimilarno difference
TUR syndrome24 / 1,0004 / 1,000B-TURP lower (RR 0.17, 95% CI 0.09 to 0.30; moderate certainty)[5]
Transfusion48 / 1,00020 / 1,000B-TURP lower (RR 0.42, 95% CI 0.30 to 0.59; moderate certainty)[5]
Erectile dysfunctionsimilarsimilarno difference
Urinary incontinence——Difference uncertain at 12 mo (RR 0.20, 95% CI 0.01–4.06; 751 men, 4 RCTs; low certainty)[5]
Retreatment (re-TURP)——Difference uncertain within follow-up up to 12 mo (RR 1.02, 95% CI 0.44–2.40; 652 men, 6 RCTs; low certainty)[5]
Bladder neck contracture (one RCT, 137 men)0%8.5%Isolated 12-month finding; most trials and meta-analyses found no difference in stricture or contracture rates.[9][22]

In moderate-to-large prostates specifically, a meta-analysis of 3 RCTs and 4 observational studies (496 patients) found B-TURP had shorter length of stay (p = 0.01), shorter catheterization (p = 0.05) and lower TUR syndrome (p = 0.03), with no difference in Qmax at 3, 6 or 12 months.[10]

Safety profile​

The Bavarian statewide multicenter prospective study (n = 10,654) is the largest contemporary safety dataset.[4]

Perioperative​

In a comparative bipolar TURP series with uninterrupted antithrombotic treatment, outcomes with aspirin (n = 130) were comparable to untreated controls (n = 73). Clopidogrel (n = 16) was associated with more transfusions (19% versus 1%) and rehospitalizations (19% versus 3%); phenprocoumon (n = 57) was associated with more postoperative retention (18% versus 6%). These small groups inform agent-specific preoperative risk assessment.[22]

  • 30-day mortality was 0.10% (historical figures 0.2–0.4%).[4][11][6]
  • 90-day mortality after TURP was 1.16% in a Finnish nationwide cohort of 39,320 patients undergoing BPH surgery (1.10% overall), and excess 90-day mortality was < 0.5% in all age groups.[12]
  • Cumulative short-term morbidity 11.1%.[4]
  • Transfusion 2.9% in the Bavarian statewide cohort (prospective, 2002–2003, n = 10,654, mixed community and academic practice, technique not stratified by monopolar/bipolar).[4] A separate literature review spanning three decades of practice reports a lower recent-era rate; see below.[13]
  • TUR syndrome 1.4% in the Bavarian cohort; 24 per 1,000 with monopolar and 4 per 1,000 with bipolar TURP in the Cochrane review.[4][5]
  • Clot retention 2–5%.[13]
  • UTI 1.7–3.6%.[4][13]
  • Failure to void / AUR 5.8–6.8%.[4][7]
  • Surgical revision (all causes) was 5.6% in the Bavarian cohort; the cited review reported 2% clot retention in its recent-era data.[4][13]

Late​

  • Urethral stricture 2.2–9.8%.[13]
  • Bladder-neck contracture 0.3–9.2%.[13]
  • Late stress urinary incontinence was reported at <0.5% in the cited general TURP review.[13] In one single-center series, 19 of 70 men who were continent before their first post-radiation TURP (27%) reported new incontinence of any type at assessment six to twelve months after surgery.[35]

Three-decade temporal trend​

A separate review pooled MEDLINE data (1989–2005), a 2003 regional quality-management dataset and long-term experience at three German centers, and reported complication rates falling across three periods (early 1979–1994 vs recent 2000–2005)[13]. This pooled recent-era transfusion rate (0.4%) is lower than the single-cohort Bavarian figure above (2.9%) and the two datasets differ in design and case mix:

OutcomeHistoricalRecent era
Transfusion7.1%0.4%
TUR syndrome1.1%0.0%
Clot retention5%2%
UTI8.2%1.7%
Mortality0–0.25% (range across the review)not reported separately

Sexual function​

Ejaculatory dysfunction is a major quality-of-life trade-off of conventional TURP. For selected men who prioritize antegrade ejaculation, supramontanal-sparing TURP preserves tissue around the verumontanum; a 2026 synthesis of six studies (540 men overall) found less retrograde ejaculation than with standard TURP (RR 0.26, 95% CI 0.14–0.46), with no clear difference detected in short-term IPSS, Qmax or PVR. Follow-up was 3–12 months, so long-term durability and safety remain uncertain.[33]

  • Retrograde ejaculation occurs in 60–75% and is the most common sexual side effect.[3][14] In Muntener 2007, 1,014 men were evaluated, but 988 returned the baseline DAN-PSSsex questionnaire and 642 returned it at four months; mean ejaculatory-function scores worsened significantly from 1.27 to 2.34 among respondents.[14]
  • The JAMA review lists erectile dysfunction at 14% after TURP.[3] The Muntener series found erectile function scores did not change significantly after TURP (p = 0.11), and 3 of 4 patients remained sexually active.[14]
  • In a meta-analysis of 10 RCTs (Liu 2020), endoscopic enucleation had slightly higher IIEF-5 scores than TURP at 48 mo and later (mean difference about 1 point), and retrograde ejaculation rates did not differ significantly.[15]
  • For bothersome loss of antegrade ejaculation after TURP, particularly when fertility is desired, sympathomimetics (including pseudoephedrine and dextroamphetamine) and imipramine, an antimuscarinic, have been described for retrograde ejaculation or ejaculatory failure from other causes. The cited dextroamphetamine trial involved men after retroperitoneal lymphadenectomy; efficacy after TURP and comparative superiority are unestablished. Sympathomimetics can cause hypertension, and sperm retrieval from post-ejaculatory urine has been described for retrograde ejaculation.[25]

Mechanism of dysfunction[16]​

  • Retrograde ejaculation follows impaired bladder-neck closure during emission, allowing semen to enter the bladder. Orgasm is usually preserved, although its quality may change.[25][26]
  • Erectile dysfunction: potential thermal or mechanical injury to the neurovascular bundles via posterolateral capsular perforation.
  • B-TURP may reduce thermal damage, but the Cochrane review found similar erectile function (IIEF-5) with the two techniques.[5]

Retreatment and durability​

SourcenFollow-upReported endpoint and rate
He 2023 SR (pooled monopolar TURP surgical reoperation)[17]130,106 overall (119 studies; 10 procedures)1 / 2 / 3 / 5 yr4.0% / 5.0% / 6.0% / 7.7%
Eredics 2018 Austrian nationwide[11]20,3888 yr8.3% re-TURP; 12.7% all endourological
Frendl 2021 New York ambulatory claims[18]15,982 (36% TURP)7 yr15.3% (failure = reoperation or AUR > 30 d)
Nackeeran 2025 VA nationwide, TURP after 2001[19]35,8175 yr15.4% (new procedure within 5 yr); OR 1.49 vs TURP before 2001
Wei 2025 JAMA review[3]—24 mo5%

The Bavarian cohort reported surgical revision in 5.6% of 10,654 TURP patients as a short-term complication.[4]

In the VA cohort, TURP after 2001 was associated with 49% higher odds of a new procedure within 5 yr than TURP before 2001 (OR 1.49, p < 0.001), and more men were on BPH medication afterward. The authors suggested that reduced trainee exposure may contribute.[19]

TURP vs other BPH procedures​

ParameterTURPAEEPAquablationGreenLight PVPUroLiftRezūm
Volume30–80 mL EAU standard; selected cases up to 150 mL reported[22][8]Any30–80 mL EAU strong recommendation; 80–150 mL single-arm evidence[22]≤ 80 mL30–80 cc (AUA)[21]; < 70 mL, no middle lobe [22]30–80 mL
IPSS Δ 12 mo−15.1−12 to −14−15.1−14.3−11.1−11.3
Qmax Δ 12 mo+10.6+14.0+10.3+12.1+4.0+5.6
5-yr surgical reoperation / retreatment7.7% (pooled monopolar TURP)[17]6.6% (HoLEP only)[17]4.1% (AquaBeam)[17]7.1% (PVP, pooled)[17]13.6% (L.I.F.T. trial)[22]4.4% (trial)[22]
Ejaculatory outcome (definitions vary)60–75% retrograde ejaculation[3][14]Mid-term retrograde ejaculation rates similar to TURP in meta-analyses[22]10% anejaculation at 6 mo among sexually active men in WATER[31]Pooled RCTs found retrograde ejaculation rates similar to TURP[22]Low incidence of sexual side effects[22]Antegrade ejaculation preserved in 98% at 12 mo in one RCT[22]
Erectile function14% erectile dysfunction in JAMA review[3]Probably similar to TURP within 12 mo in HoLEP trials[34]IIEF measured in WATER; no comparable ED event rate reported[31]Erectile function similar to TURP in comparative studies[22]Erectile function stable or slightly improved through 24 mo in a systematic review[22]Erectile function preserved in cited trials[22]
Tissue for pathologyYesYesYesNoNoNo
AnesthesiaGeneral / spinalGeneral / spinalGeneral / regionalGeneral / spinalLocal / sedationLocal / sedation

A September 2026 Cochrane review found probably similar repeat-surgery rates for HoLEP and TURP within 12 months and insufficient randomized evidence to resolve their longer-term retreatment difference.[34]

TURP has been considered a technically demanding procedure that takes significant experience to master. A pooled analysis of contemporary RCTs of monopolar TURP showed a mean resection time of 38.5 min, which suggested improved resection efficiency over earlier decades.[7]

Training-volume considerations:

  • In the Nackeeran 2025 VA analysis, TURP after 2001 was associated with 49% higher odds of a new procedure within 5 yr than TURP before 2001. The authors raised reduced trainee exposure as one possible explanation.[19]
  • The UNBLOCS investigators reported approximately 25,000 UK prostate operations annually to relieve benign prostatic obstruction, with TURP accounting for approximately 80% of them.[20]
  • A learning curve of 50–100 supervised cases is commonly quoted for proficiency.

Follow-Up​

EAU 2026 suggests reassessment four to six weeks after catheter removal to review symptom response, adverse events, IPSS/ICIQ-MLUTS, uroflowmetry, PVR, and erectile and ejaculatory function. After that review, further reassessment is unnecessary if symptoms have improved and no adverse events remain.[22]

Where TURP fits in 2026​

Distinguishing strengths​

  • Efficacy. A meta-analysis of 20 RCTs with follow-up of up to 5 yr reported a 70% IPSS reduction; Qmax also improved after TURP.[1][3]
  • Tissue for histology. Incidental prostate cancer was found in 9.8% of specimens in the Bavarian cohort.[4]
  • Availability. No specialized equipment beyond a standard resectoscope is needed.
  • Median lobes. TURP treats obstructive median lobes.
  • Complication profile. Reported morbidity and mortality have declined across three decades.[13]

Principal limitations​

  • Ejaculatory effects. Standard TURP can impair ejaculation.[3][14] WATER instead measured anejaculation at six months among sexually active men without baseline anejaculation: 36% after TURP versus 10% after Aquablation.[31]
  • Size. The AUA Panel's expert opinion is that monopolar TURP suits glands ≤ 80 cc.[21] TURP has been reported in glands up to about 150 mL by experienced surgeons[8], and enucleation is generally preferred for very large glands.
  • Hospital stay. The pooled length of stay was 3.6 d, longer than with office-based MISTs.
  • Trainee exposure. Exposure may be declining in the era of medical therapy and MISTs.[19]

EAU 2026 recommends TURP for 30–80 mL glands , HoLEP as an alternative to TURP or open surgery , and Aquablation for 30–80 mL glands particularly when preserving ejaculation is a priority .[22] In its 2020 introduction, UNBLOCS described TURP as about 80% of approximately 25,000 annual UK operations for benign prostatic obstruction.[20]

See Also​

BPH & Male LUTS — chooser · AEEP (HoLEP / ThuLEP / ThuFLEP / BipolEP) · Simple Prostatectomy · Aquablation · GreenLight PVP · UroLift · Rezūm · iTIND · Optilume BPH · PAE

References​

1. Arnold MJ, Gaillardetz A, Ohiokpehai J. Benign prostatic hyperplasia: rapid evidence review. Am Fam Physician. 2023;107(6):613-622. PMID 37327163

2. Agrawal MS, Mishra DK. Transurethral resection of prostate. J Endourol. 2022;36(S2):S29-S34. doi:10.1089/end.2022.0305

3. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men. JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045

4. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249. doi:10.1016/j.juro.2008.03.058

5. Alexander CE, Scullion MM, Omar MI, et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019;12:CD009629. doi:10.1002/14651858.CD009629.pub4

6. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361(9366):1359-1367. doi:10.1016/S0140-6736(03)13073-5

7. Mayer EK, Kroeze SG, Chopra S, Bottle A, Patel A. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012;110(11):1595-1601. doi:10.1111/j.1464-410X.2012.11119.x

8. Muzzonigro G, Milanese G, Minardi D, et al. Safety and efficacy of transurethral resection of prostate glands up to 150 mL: a prospective comparative study with 1 year of followup. J Urol. 2004;172(2):611-615. doi:10.1097/01.ju.0000131258.36966.d1

9. Stucki P, Marini L, Mattei A, et al. Bipolar versus monopolar transurethral resection of the prostate: a prospective randomized trial focusing on bleeding complications. J Urol. 2015;193(4):1371-1375. doi:10.1016/j.juro.2014.08.137

10. Bruce A, Krishan A, Sadiq S, Ehsanullah SA, Khashaba S. Safety and efficacy of bipolar transurethral resection of the prostate vs monopolar transurethral resection of prostate in the treatment of moderate-large volume prostatic hyperplasia: a systematic review and meta-analysis. J Endourol. 2021;35(5):663-673. doi:10.1089/end.2020.0840

11. Eredics K, Wachabauer D, Röthlin F, Madersbacher S, Schauer I. Reoperation rates and mortality after transurethral and open prostatectomy in a long-term nationwide analysis: have we improved over a decade? Urology. 2018;118:152-157. doi:10.1016/j.urology.2018.04.032

12. Salmivalli A, Ettala O, Boström PJ, Kytö V. Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World J Urol. 2022;40(7):1785-1791. doi:10.1007/s00345-022-03999-0

13. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP) — incidence, management, and prevention. Eur Urol. 2006;50(5):969-979. doi:10.1016/j.eururo.2005.12.042

14. Muntener M, Aellig S, Kuettel R, et al. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol. 2007;52(2):510-515. doi:10.1016/j.eururo.2007.01.088

15. Liu Y, Cheng Y, Zhuo L, et al. Impact on sexual function of endoscopic enucleation vs transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. J Endourol. 2020;34(10):1064-1074. doi:10.1089/end.2020.0141

16. Mykoniatis I, Renterghem KV, Sokolakis I. How can we preserve sexual function after ablative surgery for benign prostatic hyperplasia? Curr Drug Targets. 2021;22(1):4-13. doi:10.2174/1389450121666200925143916

17. He W, Ding T, Niu Z, et al. Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review. Front Endocrinol. 2023;14:1287212. doi:10.3389/fendo.2023.1287212

18. Frendl DM, Chen YW, Chang DC, Kim MM. A claims-based assessment of reoperation and acute urinary retention after ambulatory transurethral surgery for benign prostatic hyperplasia. J Urol. 2021;205(2):532-538. doi:10.1097/JU.0000000000001390

19. Nackeeran S, Morgan KM, Chen H, et al. The 21st century marks a rise in TURP retreatment rates: an analysis of Veterans Health Administration data. World J Urol. 2025;43(1):701. doi:10.1007/s00345-025-06083-5

20. Hashim H, Worthington J, Abrams P, et al. Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial. Lancet. 2020;396(10243):50-61. doi:10.1016/S0140-6736(20)30537-7

21. Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline (2026). Part III: Procedural and surgical management. J Urol. 2026;216(2):161-170. doi:10.1097/JU.0000000000005099

22. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS. 2026 (March update). Official full guideline. See sections 5.3.1.a and 5.4.

23. Hahn RG. Fluid absorption in endoscopic surgery. Br J Anaesth. 2006;96(1):8-20. doi:10.1093/bja/aei279

24. Adrogué HJ, Tucker BM, Madias NE. Diagnosis and management of hyponatremia: a review. JAMA. 2022;328(3):280-291. doi:10.1001/jama.2022.11176

25. Parnham A, Serefoglu EC. Retrograde ejaculation, painful ejaculation and hematospermia. Transl Androl Urol. 2016;5(4):592-601. doi:10.21037/tau.2016.06.05

26. Shindel AW, Althof SE, Carrier S, et al. Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 (2020 guideline).

27. European Association of Urology. EAU Guidelines on Urological Infections. 2026. Official guideline.

28. Anderson DR, Morgano GP, Bennett C, et al. "American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients." Blood Adv. 2019;3(23):3898-3944. doi:10.1182/bloodadvances.2019000975

29. Gilling PJ, Barber N, Bidair M, et al. "Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes." Urology. 2019;125:169-173. doi:10.1016/j.urology.2018.12.002

30. Gilling PJ, Barber N, Bidair M, et al. "Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH." Can J Urol. 2022;29(1):10960-10968. PMID:35150215

31. Gilling P, Barber N, Bidair M, et al. "WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia." J Urol. 2018;199(5):1252-1261. doi:10.1016/j.juro.2017.12.065

32. Gilling PJ, Barber N, Bidair M, et al. "Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH." Can J Urol. 2022;29(1):10960-10968. PMID:35150215

33. Yogiswara N, Rizaldi F, Soebadi MA. "The role of supramontanal preservation in ejaculation-sparing after transurethral resection of the prostate: A systematic review and meta-analysis." Cent European J Urol. 2026;79(2):161-170. doi:10.5173/ceju.2025.0175

34. Sathianathen N, Hwang EC, Brown SJ, et al. "Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia." Cochrane Database Syst Rev. 2026;9:CD013291. doi:10.1002/14651858.CD013291.pub2

35. Polland A, Vertosick EA, Sjoberg DD, et al. "Preoperative symptoms predict continence after post-radiation transurethral resection of prostate." Can J Urol. 2017;24(4):8903-8909. PMID:28832309

36. B. Braun Medical Inc. 5% Mannitol Irrigation [package insert]. Revised March 2009. NDC 0264-2303-50/70. Prescribing information.

37. Hehir CM, Calpin GG, Cullivan O, Daly GR, Dowling GP, Davis NF. "The role of 5-alpha reductase inhibitors in transurethral resection of the prostate: a meta-analysis of randomised controlled trials." BJU Int. 2026;137(3):430-443. doi:10.1111/bju.70117